← Back to Clinical Trials
Recruiting Phase 2 NCT06914674

Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas

Trial Parameters

Condition Pancreatic Neoplasms
Sponsor Fudan University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 30
Sex ALL
Min Age 14 Years
Max Age 80 Years
Start Date 2025-03-20
Completion 2027-02-28
Interventions
Tamoxifen 20 mg

Brief Summary

Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas

Eligibility Criteria

Inclusion Criteria: 1. Age 14-80 years. 2. Histologically confirmed advanced SPTP with ER/PR+. 3. Advanced disease: * Unresectable primary tumor or distant metastasis (liver, lung, peritoneum, etc.). * Recurrent or refractory after prior surgery/systemic therapy. 4. ≥1 measurable lesion. 5. ECOG performance status 0-2. 6. Life expectancy ≥1 month. 7. Able to comply with study visits and oral medication. Exclusion Criteria: 1. Non-SPTP pathology. 2. Active gastrointestinal inflammation/infection (e.g., pancreatitis). 3. Pregnancy/lactation. 4. Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary). 5. Uncontrolled comorbidities (e.g., CNS disorders, unstable angina). 6. Conditions compromising patient safety or data integrity.

Related Trials